PFEThe Covid hangover is still real
Pfizer’s pandemic windfall is still fading, but the company is trying to tell Wall Street: don’t confuse “less Covid money” with “no growth story.” The drugmaker is raising its 2026 guidance, suggesting the rest of the portfolio is doing enough heavy lifting to offset the slump.
What’s doing the lifting?
The headline here is simple: Covid-19 sales are tumbling, but Pfizer says the broader business is helping it keep the lights bright. That matters because investors have spent the last couple of years asking the same question in slightly different costumes — what does Pfizer look like after the vaccine boom wears off?
Why you should care
If Pfizer can keep pushing its outlook higher while the pandemic-era revenue shrinks, that’s a pretty decent sign the company is building a more normal, less weirdly seasonal business. If it can’t, then the stock is still going to trade like it’s stuck in post-pandemic therapy.
Big picture: Pfizer is trying to graduate from “the company that sold the world its way out of lockdown” into something sturdier. Wall Street tends to reward that kind of makeover — eventually.